• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Jubilant Therapeutics Appoints Chief Scientific Officer

    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Almac Group

    Alcami

    Syngene

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Baxter BioPharma Solutions

    Cytovance Biologics

    Syngene

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Outsourcing in China: How far can it go?

    China’s biopharmaceutical services market is on pace to top $1 billion by 2021

    Outsourcing in China: How far can it go?
    Related CONTENT
    • Asymchem
    • Trial Runners
    • SGS Life Sciences
    • Softweb Solutions
    • Vetio Animal Health
    Vicky Qing Xia, BioPlan Associates07.15.19
    In China, there are near daily trade news reports about the explosive growth in the pharmaceutical outsourcing industry, both for contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The booming biopharma industry in China has created business opportunities for CRO/CDMO companies, which is why these suppliers have become hot targets for investors. In our recent addition of “Advances in Biopharmaceutical Technology in China, 2nd ed.,” we note this increased influx of growth for CDMOs in China, and their continued future development.1

    Much of this interest in outsourcing to China has also been identified in our “16th Annual Report and Survey of Biopharmaceutical Manufacturing.”2a We asked global respondents to consider their five-year time horizon (up to 2024) and evaluate their facility’s plans for future international (not domestic) outsourcing. We identified two dozen countries as potential outsourcing destinations. Among all respondents, the U.S. ranked highest again as a potential outsourcing destination, with 41.1% indicating there was a likelihood or strong likelihood that they would outsource production to facilities there—up from 30.1% in 2018. Surprisingly, this year, China moved up to the number 2 spot, with 29%—up from 21.4% in 2018 and just 16.2% in 2017 (see Figure 1).


    Figure 1: Destination for International Outsourcing of BioManufacturing (All Respondents), next five years, 2024 (Source: 16th Annual Report and Survey of Biopharmaceutical Manufacturing, BioPlan Associates, Inc. April 2019)

    The fact that China is now being perceived globally as an outsourcing destination may have more to do with expectations that, in order to sell biologics into the rapidly growing Chinese market, U.S. and European producers may need to consider outsourced bioproduction to a Chinese partner or CMO.

    New outsourcing growth and investments
    The expansion of China’s CMO segment is continuing. For example:
    • MabPlex recently announced the opening of its newest subsidiary in Zhangjiang, Shanghai, to serve outsourcing needs for process development in Zhangjiang, a hub of dozens of biotech companies in China.2
    • WuXi Biologics, a leading global biologics technology platform company offering solutions for biologics discovery, development and manufacturing, announced in May 2019 the construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China.3
    • In July, 2016, Just Biotherapeutics, Inc., a CMO, announced the closing of a $14M Series A2 financing round. The Bill & Melinda Gates Foundation led the financing with an $8M investment followed by $2M each from existing investors such as Merck, Lilly Asia Ventures and ARCH Venture Partners. The proceeds will support the completion of new lab space, pilot plant and GMP capabilities that will enable Just Bio to accelerate the development of biologics with reduced costs.4
    • Wuxi Biologics raised HK$32 billion ($4.1 billion USD) in 2017 via an IPO through the Hong Kong Market. Some analysts say this is a growth period for China’s Pharma outsourcing industry.3
    Pharma outsourcing enters high-growth period in China
    The growth of the global biopharmaceutical outsourcing service market has been quite impressive in recent years. We predict the global biopharmaceutical outsourcing service market will grow at an annual of over 12%, which is faster than the growth of the industry as a whole, as more outsourcing is done. 

    China’s growth rate is even faster, nearing 20% according to our study. The establishment of GMP compatible R&D and manufacturing facilities requires huge investment in terms of time and capital. Some pharmaceutical companies use R&D service-outsourcing to help reduce costs, enhance efficiency, and improve flexibility. This is needed to focus R&D on priority drugs. For some emerging markets (e.g., China and Singapore), local CMOs not only can make up for the shortage of the big pharmaceutical companies’ resources but can also establish new production chains. Local preferential policies and support can also facilitate the approval process and marketing in local markets. Small biotechnology companies, which usually cannot afford to build the necessary manufacturing facilities with limited resources, would have to rely on outsourcing of manufacturing to CMOs, who have mature supply chains and the capacity for production of therapeutics.

    In the past decade, China’s biopharmaceutical service market shows exceptionally strong growth potential though its history is relatively short. While ten years ago it was hard to find one competent biopharmaceutical service company in China that could meet the basic requirements for a Western client, now China is home to many excellent Chinese biopharmaceutical service companies including WuXi Biologics, MabPlex, CMAB Biopharma and JHL Biotech, Inc.

    From 2012 to 2016, China’s biopharmaceutical service market grew rapidly at an annual growth rate of nearly 30%, with the market’s size growing from approximately $105 million in 2012 to $315 million in 2016. It is expected to reach over $1 billion in 2021.1

    Driving force behind China’s rapid growth in outsourcing
    There are several driving forces behind the robust growth of the outsourcing service sector. The most important being the booming biopharma industry in China. China is one of the most rapidly growing biopharmaceutical markets. As the most populous country in the world, it is home to the largest patient group in the world, and with a growing economy with GDP second only to the U.S., urbanization and greater access to national healthcare insurance have all contributed to double digit growth of the biopharma industry over the years.

    Regulatory reforms are also brining growth opportunities to the outsourced service industry.  With both global and domestic demands on the rise, Chinese regulatory authority has made strategic moves to boost the outsourcing sector. In 2016, China started a pilot program named Market Authorization Holder (MAH) program, under which Holders of a CFDA biologics approval number are required to market the therapeutic product and take the responsibility for them, while having the option to either manufacture the drug products on their own or use contract manufacturers instead. The MAH breakthrough first starts a pilot run in 10 provinces and municipalities which is then expected to be applied to the whole country afterwards.

    In 2017 the China FDA made statements on further implementation of the reform, so it is widely expected that MAH will become applicable to the whole country in the near future and the regulatory hurdles for contract manufacturing of drugs in China finally removed. There is a total of 381 applications of MAH, and Shanghai alone has 16 applicants of MAH for 24 drug projects with 18 contract manufacturing partners.6

    According to Boehringer Ingelheim’s contract manufacturing base in Shanghai, which is the first multinational biologics CMO in China and the company which has lobbied for the MAH reforms, even before it officially started operation in 2017, demands for services had been booked well into 2019.

    Mr. Li Zhiliang, chief executive officer of Autek Bio, stated in the 2nd edition of Advances in China’s Biopharma that China has over 50% idle capacity in biomanufacturing while this percentage is below 30% in US/EU. He expected the implementation of MAH to significantly decrease idle capacity, leading to a cost reduction and increased productivity.1 Another strategic move, which gives green light to Phase I clinical trial for MNC Pharma, is also widely expected to bring growth opportunities for clinical trial CROs in China.

    Another factor is the coming of age of biosimilar therapeutics, especially that of mAb therapeutics in China. While it is a global phenomenon that the prosperity of the biosimilar market is likely to advance the business of CMOs as developers tend to outsource the relevant R&D services to a greater extent due to a lower profit margin compared with that of innovative drugs, many of the venture capital (VC) backed Chinese biopharma companies have to use CMOs as they are too cash-strapped to build their own facilities. A country which launched its first made-in-China mAb therapeutics only in 2005, China is experiencing a spike in mAb drug development in recent years.

    BioPlan’s Advances in Biopharmaceutical Technology in China study shows that over 250 mAb therapeutics are under clinical development in China, with CD20, HER2, EGFR, VEGF, TNF-alpha as the hottest targets (see Figure 2).1 This wave of mAb therapeutics development was initiated only around a decade ago, with the majority of developers starting their mAb development within the past 5 years or so. Regulatory authorities in China have just started approving this wave of mAb projects, as the last 7 months has witnessed three PD-1 mAb therapeutics made by domestic companies been approved, but the peak has certainly not arrived yet. New investments are still coming into this sector, and new companies are being founded in the past few years with a focus on mAb therapeutics. 


    Figure 2: Hottest Target for mAb Drugs Under Development in China.

    BioPlan’s internal studies have shown industry consensus that in the next 5 years China will see double digit mAb therapeutics from domestic companies getting BLAs. In the next 5 years, demands for new capacity in bio-processing as well as R&D will certainly be higher than it is today. As a result, some CMOs are actively increasing their capacity to meet market demand.  WuXi Biologics plans to have more than 220,000L manufacturing capacity by 2021,3 and BI Shanghai has also increased its capacity of contract biologics manufacturing by 2,000L in the spring of 2019.6 

    Local government support is also contributing to the growth of the outsourcing sector for biopharma industry. There have been multiple cases of municipal government providing cheap lease of land or other forms of subsidiary for CMO companies. For example, in November 2018, with local government support and subsidies, Wuxi Biologics started construction on a Biologics Manufacturing Center of excellence in Shijiazhuang, Hebei Province. The new Biologics Center with 48,000L bioreactor capacity, one of the largest global facilities using disposable bioreactors, will be built to meet cGMP standards of the U.S., the EU, and China.2

    What will happen next?
    Though China’s pharma outsourcing sector keeps attracting new investments, analysts expect that the current leaders will continue to dominate. Wuxi Biologics just started operation of a new facility, which is the largest mammalian cell culture manufacturing facility, as well as the largest biologics manufacturing facility in China.3 3S Guojian, which successfully launched the first made-in-China mAb therapeutics in China, also uses its idle capacity for contract manufacturing and has good reputation in the industry. 

    Since 2016, there are new CMOs starting their operations, and it is expected that with biopharmaceutical companies building new product lines now, many would like to conduct contract manufacturing using their idle capacity. Market demand may also cool over the next decade as many bio-similar drugs may not be as profitable as investors expect, leading to fierce competition along with mergers and acquisitions in the field.

    We also expect that the quality standards for manufacturing will rise in China as the leading CMOs put forth great efforts to ensure GMP world-class manufacturing operations; they recognize that one failure may ruin the industry’s reputation. With the improvement and progress in contract bio-processing, some are projecting that contract manufacturing may help transform China’s biopharma industry, enabling outsourcing manufacturing to become a mainstream solution that allows biopharma companies to concentrate on innovation in drug development.

    How far will it go?
    While regulatory reforms bring good news to China’s biopharma outsourcing industry, a majority of domestic biopharma developers, aside from smaller startups, remain cautious about outsourcing all of their manufacturing. 

    BioPlan’s surveys of China’s biopharma companies have shown that over 90% already have or are still building their own facilities. For example, BeiGene, a company already using a CMO as its manufacturing partner, is also building a bio-manufacturing facility in Guangzhou. Major concerns regarding outsourcing, however, remain, and include quality issues/loss of control, lack of reliable contract manufacturing companies, no commercial insurance for risk sharing, as well as little experience in manufacturing partnership management and auditing. 

    Industry insiders also have concerns over how to clearly define the MAH holder, and one’s manufacturing partner’s responsibility in legal contracts. Some have suggested that a certification system might be necessary for contract manufacturing organizations. As far as providing service for multi-national pharma companies, concerns about cGMP compliance remains the biggest issue. These issues, are, however, being sorted out. For example, Wuxi Biologics received EMA GMP certificates for the production of Trogarzo at its cGMP drug substance (DS) and drug product (DP) manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai on March 2019. This is a milestone for China’s service providers and a good sign as domestic CMOs struggle to win commercial manufacturing projects from Western pharmaceutical clients. 

    References
    1. Advances in Biopharmaceutical Technology in China, Soc. Ind. Microbiology, and BioPlan Associates, Inc. 2018
    2a. 16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity, BioPlan Associates, Inc. April 2019
    2. MabPlex Company Website.
    3. Wuxi Biologics Website
    4. “Just Biotherapeutics, Inc. Secures $14M Series A2 Funding to Build Laboratory, Pilot Plant and GMP Capabilities”. Business Wire, July 25, 2016
    5.  Du, Chewei. Liberation Daily, Oct 10, 2017.
    6.  Boehringer-Ingelheim Shanghai Website.


    Vicky Qing Xia
    BioPlan Associates

    Vicky Qing Xia, Project Director, BioPlan Associates has her MS in biology from University of Texas-Houston, MBA from University of Pittsburgh. She has experience in consulting, business development, as well as alliance management in China’s bio-pharmaceutical industry. Her expertise includes developing research and analysis on multiple global market segments, and has managed a team of industry experts and projects.
    Related Searches
    • outsourced
    • CDMO
    • biologics
    • cgmp compliance
    Suggested For You
    Asymchem Asymchem
    Trial Runners Trial Runners
    SGS Life Sciences SGS Life Sciences
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Roche Wins Two Approvals for Cancer Drug Rozlytrek Roche Wins Two Approvals for Cancer Drug Rozlytrek
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    WuXi Biologics Plans to Further Expand New Bioconjugation Center WuXi Biologics Plans to Further Expand New Bioconjugation Center
    Sierra’s Momelotinib Granted FDA Fast Track Designation Sierra’s Momelotinib Granted FDA Fast Track Designation
    Risk-Based Monitoring Risk-Based Monitoring
    The Orphan Promise The Orphan Promise
    Evotec Receives $23.8M TB Grant  Evotec Receives $23.8M TB Grant

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Biologics, Proteins, Vaccines
      Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18

    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17


    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17


    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17

    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17

    • Biologics, Proteins, Vaccines

      Year-End Trends in Biopharma Contract Manufacturing

      Budgets are flattening, but some CMOs are well positioned for growth
      Eric S. Langer, BioPlan Associates 11.09.16


    • Biologics, Proteins, Vaccines

      Economics of In-House Buffer Preparation

      Evaluating the cost effectiveness of keeping basic ops in-house
      Eric S. Langer, BioPlan Associates 09.08.16

    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    Trending
    • Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement For Novavax’ COVID-19 Vaccine
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Pharmaron Acquires Biomanufacturing Site In The UK From AbbVie
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Diets High In Fructose Could Cause Immune System Damage
    Nestlé Acquires Premium Water Brand Essentia
    Kaneka Probiotics Announces Launch of L. plantarum DR7
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs First OTC Home Molecular COVID-19 Test
    FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    Cross Border Venture Financing Rose in Final Quarter of 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sharp Appoints EU Qualified Person
    Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
    Metrics Contract Services Completes Russian Regulatory Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    It's International Women's Day—But What Does That Mean?
    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Happi

    Latest Breaking News From Happi

    Cococare Appoints First Woman President
    Ross Highlights Triple Shaft Mixers
    Arm & Hammer Unveils Foot Wipes
    Ink World

    Latest Breaking News From Ink World

    Capital Printing Invests in 2nd Komori Press
    Arna Marketing Adds Canon’s ProStream, VarioPRINT iX Production Inkjet Presses
    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Xeikon details upcoming Xeikon Café TV seminars
    Resource Label Group acquires New England Label
    UV+EB-cured products rated 'easier to recycle'
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Arm & Hammer Launches Foot Wipes
    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Australia Clears Conformis' iTotal PS Knee Replacement System
    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Wearable Patch Market to Reach $27.8 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login